Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ford Motor Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Ford Motor Company trades at $13.98 (market cap $55.83B). The key difference: Ford Motor Company is far larger — about 64.6× Amphastar Pharmaceuticals Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | F | |
|---|---|---|
Market Cap | $863.95M | $55.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $17.44 |
52-Week Low | $16.87 | $11.21 |
Enterprise Value | $1.26B | $187.79B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Ford (F) trades at $13.98, up 1.38% with a bullish technical signal despite mixed fundamentals. The company reported negative net income of -$8.18B in 2025 but maintains strong operating cash flow of $21.28B. Recent news highlights Ford's new $28,350 Fathom EV truck launch for 2027, targeting affordable electric vehicles while managing EV transition costs through its profitable commercial Pro segment.
Outlook remains cautious with analyst consensus at $16.00 (43% buy ratings). Key opportunities include EV expansion and dividend stability ($0.15 quarterly), while risks involve persistent net losses, high debt levels (56.49% debt-to-asset), and competitive EV market pressures. The stock offers value with low P/E (11.84) but requires monitoring of profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
